Compare
Genelux Corp vs Aspire Biopharma Holdings, Inc. vs Alaunos Therapeutics, Inc. vs PRF Technologies Ltd.
| Latest fiscal year | Genelux Corp GNLX | Aspire Biopharma Holdings, Inc. ASBP | Alaunos Therapeutics, Inc. TCRT | PRF Technologies Ltd. PRFX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $8.0K | $6.2K | $5.0K | $17.0K |
| Revenue growth (YoY) | 0.0% | n/a | -50.0% | n/a |
| Gross margin | n/a | -1.9% | n/a | -311.8% (computed) |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$32.15M | -$24.48M | -$4.18M | -$5.02M |
| EPS (Diluted) | -$0.86 | -$16.38 | -$2.20 | -$7.47 |
| Operating cash flow | -$25.27M | -$4.92M | -$2.87M | -$3.96M |
| Free cash flow | -$26.37M | n/a | -$2.97M | -$3.96M |
| Cash & equivalents | $5.33M | n/a | $1.39M | $3.12M |
| Total assets | $19.03M | $1.31M | $2.97M | $12.00M |
| Total liabilities | $7.48M | $7.69M | $813.0K | $2.71M |
| Shareholders' equity | $11.54M | -$6.38M | $2.15M | $8.54M |
| Return on year-end equity | -278.5% | n/a | -194.0% | -58.8% |
| Shares outstanding | 38.14M | 3.53M | 2.35M | 830.6K |
Revenue, most recent five fiscal years
| Fiscal year | Genelux Corp | Aspire Biopharma Holdings, Inc. | Alaunos Therapeutics, Inc. | PRF Technologies Ltd. |
|---|---|---|---|---|
| Latest | $8.0K Ended 2025-12-31 | $6.2K Ended 2025-12-31 | $5.0K Ended 2025-12-31 | $17.0K Ended 2025-12-31 |
| 1 year earlier | $8.0K Ended 2024-12-31 | n/a | $10.0K Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $170.0K Ended 2023-12-31 | n/a | $5.0K Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $11.07M Ended 2022-12-31 | n/a | $2.92M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $398.0K Ended 2021-12-31 | n/a |